Single Cell and Spatial Transcriptomics Studies of Fibrosis in Prospective Registry in IBD Study at MGH and GI Disease and Endoscopy Registry
Demographics (2)
- AGE - Age, by groups of 5 years, at time of collection (phv00557062.v1.p1)
- SEX - Biological sex (phv00557056.v1.p1)
Medications (6)
- TX_5_ASA - 5-ASA (mesalamine, balasalizide, azulfidine, olsalazine) treatment at time of collection (phv00557067.v1.p1)
- TX_ANTIBIOTIC - Antibiotic (flaygl, cipro, xifaxin, levaquin) treatment at time of collection (phv00557071.v1.p1)
- TX_ANTIDIARRHEAL - Antidiarrheal (lomotil, imodium, deodorized tincture of opium (DTO)) treatment at time of collection (phv00557066.v1.p1)
- TX_BIOLOGICS - Biologics (infliximab, adalimumab, certalizumab, natalizumab, golimumab, vedolizaumab, ustekinumab, tofacitinib) treatment at time of collection (phv00557068.v1.p1)
- TX_IMMUNOMODULATORS - Immunomodulators (azathioprine, methotrexate, mercaptopurine) treatment at time of collection (phv00557070.v1.p1)
- TX_STEROID - Steroid (prednisone, budesonide, medrol, IV steroid, (phv00557069.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00557061.v1.p1)
Substance Use (1)
- SMOKING - Smoking status (phv00557072.v1.p1)
Other (26)
- AGE_ONSET - Age of inflammatory bowel disease onset (Montreal classification) (phv00557063.v1.p1)
- ANALYTE_TYPE - Analyte evaluated from the sample (phv00557081.v1.p1)
- ANALYTE_TYPE - Analyte evaluated from the sample (phv00557088.v1.p1)
- BODY_SITE - Body site, here intestinal segment from which the tissue was collected (phv00557080.v1.p1)
- BODY_SITE - Body site, here intestinal segment from which the tissue was collected (phv00557086.v1.p1)
- COLLECTION_PROCEDURE - Clinical procedure used for tissue collection (phv00557087.v1.p1)
- CONSENT - Registered consent groups (Data Use Limitations (DUL)) as determined by submitters' Institutional Review Boards (IRB) or equivalent body (phv00557055.v1.p1)
- DIAGNOSIS - Diagnosis (phv00557060.v1.p1)
- DISEASE_BEHAVIOR - Disease behavior (Montreal classification) (phv00557065.v1.p1)
- DISEASE_LOCATION - Disease location (Montreal classification) (phv00557064.v1.p1)
- HISTOPATHOLOGY - Pathological evaluation of the collected tissue (phv00557074.v1.p1)
- IS_TUMOR - Tumor status of the sample (phv00557082.v1.p1)
- IS_TUMOR - Tumor status of the sample (phv00557089.v1.p1)
- SAMPLE_ID - Sample ID (phv00557073.v1.p1)
- SAMPLE_ID - Sample ID (phv00557083.v1.p1)
- SAMPLE_ID - Sample ID (phv00557058.v1.p1)
- SUBJECT_ID - Subject ID (phv00557059.v1.p1)
- SUBJECT_ID - Subject ID (phv00557054.v1.p1)
- SUBJECT_ID - Subject ID (phv00557057.v1.p1)
- TISSUE_CLASSIFICATION - Label based on histopathological and anatomical evaluation (phv00557078.v1.p1)
- TISSUE_FRACTION - Cellular fraction from the processed tissue (phv00557085.v1.p1)
- TISSUE_MUCOSA - Presence of mucosa in section (phv00557075.v1.p1)
- TISSUE_MUSCULARIS - Presence of muscularis propria in section (phv00557077.v1.p1)
- TISSUE_SPOTS_CAPTURED - Number of spots passing quality control thresholds (phv00557079.v1.p1)
- TISSUE_STATUS - Pathological evaluation of the collected tissue (phv00557084.v1.p1)
- TISSUE_SUBMUCOSA - Presence of submucosa in section (phv00557076.v1.p1)